CETP and atherosclerosis: Clinical trials involving torcetrapib, the first CETP inhibitor, were terminated early owing to off‐target toxicity,12, 13 and despite remarkable increases in HDL‐cholesterol, torcetrapib did not reduce the progression of atherosclerosis.14, 15 The definitive clinical efficacies of CETP inhibition are under investigation in the ongoing REALIZE study of anacetrapib, a more recent CETP inhibitor.16